Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

OBJECTIVE: Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Turk J Haematol
Main Authors: Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M. Cem, Öngören, Şeniz, Eşkazan, A. Emre, Soysal, Teoman, Aydın, Yıldız
Formato: Artigo
Idioma:Inglês
Publicado em: Galenos Publishing 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5544042/
https://ncbi.nlm.nih.gov/pubmed/28270368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2016.0397
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados